Analytical Data
-
Gene name
IL-28R beta
- Application
-
Alternative Names
Fibronectin type III domain containing 6 (FNDC6) (IL-20 receptor subunit beta) (IL-20R-beta) (IL-20RB) (IL-20R2) (DIRS1)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 85% as determined by SDS-PAGE. as determined by SDS-PAGE.
-
Uniprot
Q6UXL0
-
Expression Region
30-233aa
-
Molecular Weight
26.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-28R beta, or interleukin-28 receptor beta, is a crucial component of the type III interferon receptor complex, which plays a significant role in the immune response against viral infections. Researchers have been increasingly focused on IL-28R beta due to its involvement in regulating antiviral activity, particularly in the context of hepatitis C virus (HCV) infections. The receptor facilitates cellular responses to interferon lambda (IFN-λ), a type of interferon that exhibits potent antiviral properties with fewer side effects compared to traditional interferons. Understanding the structure and function of IL-28R beta is essential for exploring therapeutic strategies that leverage the immune system, particularly for patients who may not respond well to other forms of antiviral treatment. Experimental approaches, including the production of recombinant IL-28R beta proteins, aim to clarify its signaling mechanisms and interactions with IFN-λ. This research could lead to the development of novel immunotherapies that enhance the body’s antiviral defenses while minimizing adverse reactions. With the rising concerns around antiviral drug resistance and the increasing incidence of chronic viral infections worldwide, deciphering the role of IL-28R beta in immune modulation presents promising avenues for improved clinical outcomes in the management of viral diseases.
